Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CAMK2A | Q9UQM7 | 5/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429595 | 0.85 | KEAP1 (0.50) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL16041940 | 0.82 | KEAP1 (0.54) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL5429266 | 0.81 | FFAR1 (0.49) | MAPT | |
| SCHEMBL2394432 | 0.80 | KEAP1 (0.53) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL260512 | 0.80 | CHRM1 (0.57) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL29419329 | 0.80 | CHRM1 (0.57) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL27748507 | 0.79 | MAPT (0.43) | MAPT | |
| Hydrochloric Acid SCHEMBL2532568 | 0.78 | CHRM1 (0.55) | KEAP1NFE2L2CXCL8CYP2C9CHRM1 | |
| SCHEMBL5419084 | 0.78 | KMT2A (0.40) | CYP2C9 | |
| SCHEMBL4943725 | 0.77 | ABCB11 (0.43) | CAMK2AGRIK1MAPTAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324235-B2 | Heterocyclic spiro-compounds | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| EP-2134720-B1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| CN-101711252-A | heterocyclic spiro-compounds | NOVARTIS AG | 2010-05-19 | — | — | CN | disclosed |
| EP-2134720-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | Novartis Ag (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008119744-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1948630-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007052023-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | KEAP1 130/4885NFE2L2 398/4885CXCL8 2357/4885 |
| US-20100144774-A1 | HETEROCYCLIC SPIRO-COMPOUNDS | REN, NR3C2, CYP21A2 | KEAP1 595/4885NFE2L2 1617/4885CXCL8 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.